10x Genomics (TXG) Change in Receivables (2018 - 2026)

10x Genomics has disclosed Change in Receivables across 9 years of filings, most recently posting $8.5 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 428.47% year-over-year to $8.5 million; the TTM figure through Jun 2026 stood at -$2.9 million (up 93.06% YoY), while the FY2025 annual figure was -$41.3 million, down 53.29% from the prior year.
• Change in Receivables came in at $8.5 million for Q2 2026 at 10x Genomics, up from -$8.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.6 million in Q4 2022 to a low of -$35.3 million in Q1 2025.
• Average Change in Receivables over 5 years is -$2.1 million, with a median of -$209500.0 recorded in 2022.
• Year-over-year, Change in Receivables surged 3383.84% in 2023 and slumped 2024.59% in 2025.
• Over 5 years, Change in Receivables stood at $20.6 million in 2022, then tumbled by 46.78% to $11.0 million in 2023, then slumped by 60.18% to $4.4 million in 2024, then slipped by 26.04% to $3.2 million in 2025, then soared by 163.43% to $8.5 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $8.5 million in Q2 2026, -$8.0 million in Q1 2026, and $3.2 million in Q4 2025.